Clinical efficacy of arsenic trioxide combined with carboplatin for neoadjuvant chemotherapy for locally advanced cervical cancer

The First Affiliated Hospital of Guangzhou University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1 Aged 20-60 years;
•2 Patients with stage IB2, IIA2, IIB cervical cancer;
•3 Normal blood analysis, liver and kidney function before treatment;
•4 No evidence of distant metastasis;
•5 No serious heart, liver, kidney and blood system and other important organ diseases;
•6 Patients have signed the informed consent

•1 Early or small lesions do not require neoadjuvant chemotherapy patients;
•2 cachexia:PS score = 3 points, KPS score < 70 points;
•3 Active infection or bleeding;
•4 Complete intestinal obstruction;
•5 Uncontrolled psychosis;
•6 Pregnant and lactating women;
•7 Allergic constitution, or known to arsenic allergy patients;
•8 Late no possibility of surgery patients;
•9 Patients who are unwilling to receive neoadjuvant chemotherapy combined with surgery in the advanced stage;
•10 Patients with severe comorbidities;
•11 Patients who cannot tolerate chemotherapy and surgical words; 13 Patients who have participated in other clinical trials in the last 3 months;
•12 Any other conditions that the investigator considers unsuitable for participation in this trial.

发起方

The First Affiliated Hospital of Guangzhou University of Chinese Medicine